Anavex Life Sciences Corp (AVXL)

[falconer66a]

Now, the Blarcamesine Ease of Use Factor

Interesting focus of Dr. Grimmer's presentation at the European Alzheimer’s conference:

The advantage for the family would be less caregiver stress, and likely less financial strain with no need to arrange for constant transportation and no impact on own work schedule.

The advantage for the physician would be no logistical barriers to treatment with no need to arrange or schedule complex, invasive PET scans, lumbar puncture (spinal tap) or repeated MRIs.

In summary, the impact on daily life is favorable with oral Alzheimer's treatment blarcamesine. It maintains independence of loved ones longer, safely, giving better outcomes, while allowing efficiency and convenience for patients and families.

He seems to imply, contend, or presume that both blarcamesine and the approved monoclonal antibody drugs (MABs) successfully treat Alzheimer’s. But the MABs present very difficult, expensive, and procedurally complicated lab-based treatment monitoring protocols. Instead, blarcamesine is simply taken at home, each day, with a glass of water.

Let’s see how this information gets reported in commentaries derived from the conference.

How will both patients and physicians respond to this information, once it's known?